BridgeBio Pharma announces $150M public offering
- BridgeBio Pharma (NASDAQ:BBIO) said it had begun an underwritten public offering of $150M of shares of its common stock.
- BridgeBio also expects to grant the underwriters a 30-day option to purchase up to an additional $22.5M of shares.
- Goldman Sachs & Co, Evercore, and Morgan Stanley are acting as book-running managers for the proposed offering.
- Press Release